Jun 22, 2020
Acute Myeloid Leukemia (AML) - Opportunity Analysis and Forecasts to 2029
Jun 17, 2020
Leukemia Therapeutics Markets, 2015-2025 - Size by Value & Volume, Trends & Developments, Competitive Landscape
Jun 17, 2020
The Leukemia & Lymphoma Society Today Announces a Collaboration with the National Cancer Institute and Children's Oncology Group on a Global Master Clinical Trial for Children with Acute Leukemia
Jun 15, 2020
Emmes Announces Its Work on a Phase 3 Clinical Trial for Breakthrough Therapy Designation Product
Jun 12, 2020
Tolero Pharmaceuticals Presents Findings from Phase 1 Zella 101 Clinical Study Evaluating Investigational Agent Alvocidib in Patients with Newly Diagnosed Acute Myeloid Leukemia at Virtual EHA Annual Congress 2020
Jun 12, 2020
EHA25Virtual: Gut Microbiome Disturbance by Antibiotic Treatment Early in Life is Sufficient to Induce Leukemia in Predisposed Mice
May 29, 2020
Gracell Announces Two Presentations at the Annual Meeting of American Society of Clinical Oncology (ASCO)
May 19, 2020
Protocol First Announces Strategic Investment from The Leukemia & Lymphoma Society (LLS) to Advance Clinical Trial Execution
Apr 28, 2020
Gracell Reports Data of First-in-human Clinical Trial for Universal TruUCAR(TM) GC027 in Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia at the AACR Virtual Annual Meeting
Apr 28, 2020
Cardioprotective Drug Prevents Severe Cardiac Events in Children Undergoing Chemotherapy for Acute Myeloid Leukemia
Apr 27, 2020
Syndax Pharmaceuticals Announces Preclinical Profile and Initial Phase 1 Data Demonstrating Clinical Activity of Menin Inhibitor SNDX-5613 in Adults with Relapsed/Refractory Acute Leukemias
Apr 14, 2020
AVM Biotechnology has FDA Approval for Clinical Trials for Promising New Cancer Treatment
Apr 13, 2020
Gracell to Present the First-in-human, Universal TruUCAR(TM) GC027 Therapy for Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia at the AACR Annual Meeting
Apr 08, 2020
New Prognostic Tool Helps Leukemia Patients Plan for Cancer Treatment
Apr 07, 2020
Ascentage Pharma Announces Approval for the Phase Ib/II Clinical Study of Bcl-2 Inhibitor APG-2575 for the Treatment of Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma in China
Apr 03, 2020
Gracell Announces China MNPA Acceptance of Investigational New Drug Application for GC007g Cell Therapy for CD19 Positive Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
Mar 26, 2020
Tolero Pharmaceuticals Joins The Leukemia & Lymphoma Society's Groundbreaking Beat AML Master Clinical Trial for Patients with Acute Myeloid Leukemia
Mar 24, 2020
2020 B-Cell Chronic Lymphocytic Leukemia Pipeline Assessment: Therapeutics, Drugs, Companies, Developments
Mar 23, 2020
3D Genetic Structure in Blood Cancer Important Beyond DNA Code Changes
Mar 16, 2020
Bridge Medicines Enters Exclusive License Agreement with The Rockefeller University for Novel Epigenetic Leukemia Program